Perceptronix Medical Inc. Laboratories

Perceptronix Medical Inc. Laboratories

November 17, 2008 15:51 ET

Perceptronix to Exhibit at St. Paul's Hospital Annual CME Conference

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Nov. 17, 2008) - Perceptronix Medical Inc. will be exhibiting at the St. Paul's Hospital Annual Continuing Medical Education Conference from November 18 - 21. Perceptronix will be showcasing LungSign™, an innovative early lung cancer test currently available for lung cancer risk assessment, as well as premiering an instructional video demonstrating its use. The company will be exhibiting at booth 127 at the Vancouver Convention & Exhibition Centre.

LungSign™ is the first test to market to offer a safe, painless and convenient method of assessing a patient's risk of lung cancer. It is based on an automated quantitative cytology analysis of sputum. LungSign™ also serves as a highly relevant and useful complement to current radiological diagnostic methods (e.g. CT).

"We're please to have the LungSign™ instructional video ready for the St. Paul's CME conference," stated Bojana Turic, MD, Perceptronix President and CEO. "The video will provide added guidance for both patients and physicians regarding use of the LungSign™ kit."

About Perceptronix Medical Inc.

Perceptronix Medical Inc. (Vancouver, Canada) is a private laboratory and cancer diagnostics company specializing in the provision of innovative early cancer detection tests based on quantitative cytology. The Company's DNA image cytometry technology was developed in partnership with the British Columbia Cancer Agency (Vancouver, Canada). Quantitative cytology provides physicians with an innovative cytopathology assessment based on an objective measure of large-scale DNA abnormality that can indicate precancerous or cancerous changes. In addition to general quantitative cytology services, the company has developed pioneering tests for the early detection of lung cancer and oral cancer.

Contact Information